Abbott Laboratories  

(Public, NYSE:ABT)   Watch this stock  
Find more results for John S. Blaser
Aug 31 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 39.28 - 51.74
Open     -
Vol / Avg. 0.00/6.63M
Mkt cap 68.59B
P/E 28.73
Div/yield 0.24/2.12
EPS 1.58
Shares 1.49B
Beta 0.67
Inst. own 71%
Oct 20, 2015
Q3 2015 Abbott Laboratories Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 22, 2015
Q2 2015 Abbott Laboratories Earnings Release
Jul 22, 2015
Q2 2015 Abbott Laboratories Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 15.20% 8.50%
Operating margin 14.10% 12.75%
EBITD margin - 21.29%
Return on average assets 7.23% 4.09%
Return on average equity 14.05% 7.37%
Employees 77,000 -
CDP Score - 93 B


100 Abbott Park Rd
ABBOTT PARK, IL 60064-3500
United States - Map
+1-847-9376100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Officers and directors

Miles D. White Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Brian B. Yoor Chief Financial Officer, Senior Vice President - Finance
Bio & Compensation  - Reuters
Thomas C. Freyman Executive Vice President - Finance and Administration
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Hubert L. Allen Executive Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Stephen R. Fussell Executive Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard W. Ashley Executive Vice President - Corporate Development
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Brian J. Blaser Executive Vice President - Diagnostics Products
Age: 50
Bio & Compensation  - Reuters
John M. Capek Ph.D. Executive Vice President - Ventures
Age: 53
Bio & Compensation  - Reuters
Heather L. Mason Executive Vice President, Nutritional Products, Global Commercial Operations.
Age: 54
Bio & Compensation  - Reuters
Michael J. Warmuth Executive Vice President - Established Pharmaceuticals
Age: 52
Bio & Compensation  - Reuters